 |
|
New drug lets thyroid cancer patients avoid nasty side effects during treatment
January 10, 2006A multicenter international study, including Johns Hopkins, has found that after surgery for thyroid cancer, giving genetically engineered human thyroid-stimulating hormone (rhTSH) before radioiodine treatment avoids the previous need to stop thyroid replacement therapy and the miserable side effects that go with it.
The study, led by Paul Ladenson, M.D., director of the Division of Endocrinology at The Johns Hopkins University School of Medicine, and Furio Pacini at the University of Siena in Italy, was reported in the December online edition of the Journal of Clinical Endocrinology and Metabolism.
Typically, radioiodine treatment for cancer of the thyroid gland requires temporary discontinuation of thyroid hormone replacement for several weeks, leading to weight gain, constipation, fatigue, slowed thinking, depressed mood, muscle cramps, intolerance of cold temperatures and other symptoms. "This study shows that patients who use a recombinant form of TSH can continue their thyroid replacement therapy and enjoy a better quality of life during their cancer treatment," Ladenson says.
Thyroid cancer is first treated by surgical removal of the gland in the neck, often followed by radioactive iodine treatment to remove any remaining thyroid tissue.
Once the thyroid is diseased or removed, it no longer produces the hormones T4 (thyroxine) and T3 (triiodothyronine), which help regulate heart rate, blood pressure, body temperature and weight. Therefore, it is essential to add back the thyroid hormone L-thyroxine to keep the body functioning normally. Paradoxically, for radioiodine treatment to be effective, thyroid hormone treatments previously had to be suspended, according to Ladenson. Suspending hormone treatments stimulates the pituitary gland to produce thyroid-stimulating hormone (TSH). TSH stimulates any remaining thyroid tissue to concentrate the radioiodine, which can then eliminate remaining thyroid tissue. Once inside the cell, radioiodine emits beta particles that damage the DNA in thyroid cells without affecting surrounding tissues, according to Ladenson.
TSH made by the pituitary gland and rhTSH produce equivalent biological actions, according to Ladenson, and there are only slight structural differences.
"This multi-institutional study proved that rhTSH is just as effective as the TSH produced by the body in destroying these remaining thyroid cells," Ladenson says.
This randomized, controlled, study involved 60 patients from four centers in Europe and five in North America. The first patient was enrolled on Dec. 17, 2001, and the last patient completed the final study visit on Sept. 26, 2003.
Within 14 days after surgical removal of the thyroid, 32 of these patients were randomized to a group that received their thyroid hormone treatment, L-thyroxine, without interruption and rhTSH for four to six weeks prior to radioiodine treatment. Twenty-eight were randomized to a group that did not receive L-thyroxine or rhTSH and were then treated after hypothyroidism prompted their own pituitary glands to make TSH. Quality of life was tested during this period and symptoms were assessed using the Billewicz scale - an observer-rated evaluation of 14 symptoms and signs exhibited by patients who have a lack of thyroid hormone in their system. Patients then underwent radioiodine treatment. Eight months after this treatment, doctors performed a scan to determine if there was any remaining thyroid tissue.
Before radioiodine treatment, Billewicz scores revealed both groups to be comparable - with mild and transient symptoms reported by only eight patients in each group. As they were prepared for radioiodine treatment, the group denied thyroid hormone therapy had significantly higher total symptom scores at weeks two and four. The most common complaints of patients who were denied thyroid hormone therapy, vs. patients who received thyroid hormone therapy and rhTSH, were cold intolerance (50 percent vs. 21 percent), weight increase (60 percent vs. 21 percent), constipation (43 percent vs. 3 percent), lethargy (50 percent vs. 12 percent), cold skin (47 percent vs. 12 percent), and puffiness around the eyes (50 percent vs. 0 percent).
Eight months after radioiodine therapy, tests showed that remaining thyroid cells had been successfully destroyed in all patients in both groups, according to the study.
These results clearly indicate that rhTSH combined with radiation therapy successfully destroys remaining thyroid tissue without the need to discontinue thyroid hormones, thus reducing the unpleasant side effects generally associated with this treatment, Ladenson says.
Johns Hopkins Medical Institutions
Thyroid cancer is first treated by surgical removal of the gland in the neck, often followed by radioactive iodine treatment to remove any remaining thyroid tissue.
Once the thyroid is diseased or removed, it no longer produces the hormones T4 (thyroxine) and T3 (triiodothyronine), which help regulate heart rate, blood pressure, body temperature and weight. Therefore, it is essential to add back the thyroid hormone L-thyroxine to keep the body functioning normally. Paradoxically, for radioiodine treatment to be effective, thyroid hormone treatments previously had to be suspended, according to Ladenson. Suspending hormone treatments stimulates the pituitary gland to produce thyroid-stimulating hormone (TSH). TSH stimulates any remaining thyroid tissue to concentrate the radioiodine, which can then eliminate remaining thyroid tissue. Once inside the cell, radioiodine emits beta particles that damage the DNA in thyroid cells without affecting surrounding tissues, according to Ladenson.
TSH made by the pituitary gland and rhTSH produce equivalent biological actions, according to Ladenson, and there are only slight structural differences.
"This multi-institutional study proved that rhTSH is just as effective as the TSH produced by the body in destroying these remaining thyroid cells," Ladenson says.
This randomized, controlled, study involved 60 patients from four centers in Europe and five in North America. The first patient was enrolled on Dec. 17, 2001, and the last patient completed the final study visit on Sept. 26, 2003.
Within 14 days after surgical removal of the thyroid, 32 of these patients were randomized to a group that received their thyroid hormone treatment, L-thyroxine, without interruption and rhTSH for four to six weeks prior to radioiodine treatment. Twenty-eight were randomized to a group that did not receive L-thyroxine or rhTSH and were then treated after hypothyroidism prompted their own pituitary glands to make TSH. Quality of life was tested during this period and symptoms were assessed using the Billewicz scale - an observer-rated evaluation of 14 symptoms and signs exhibited by patients who have a lack of thyroid hormone in their system. Patients then underwent radioiodine treatment. Eight months after this treatment, doctors performed a scan to determine if there was any remaining thyroid tissue.
Before radioiodine treatment, Billewicz scores revealed both groups to be comparable - with mild and transient symptoms reported by only eight patients in each group. As they were prepared for radioiodine treatment, the group denied thyroid hormone therapy had significantly higher total symptom scores at weeks two and four. The most common complaints of patients who were denied thyroid hormone therapy, vs. patients who received thyroid hormone therapy and rhTSH, were cold intolerance (50 percent vs. 21 percent), weight increase (60 percent vs. 21 percent), constipation (43 percent vs. 3 percent), lethargy (50 percent vs. 12 percent), cold skin (47 percent vs. 12 percent), and puffiness around the eyes (50 percent vs. 0 percent).
Eight months after radioiodine therapy, tests showed that remaining thyroid cells had been successfully destroyed in all patients in both groups, according to the study.
These results clearly indicate that rhTSH combined with radiation therapy successfully destroys remaining thyroid tissue without the need to discontinue thyroid hormones, thus reducing the unpleasant side effects generally associated with this treatment, Ladenson says.
Johns Hopkins Medical Institutions
Thyroid Cancer Current Events and Thyroid Cancer News RSSNewly revised guidelines for managing thyroid cancer published in Thyroid journal
The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer.
Study examines complications of thyroid surgery in older patients
In a study of patients undergoing thyroid surgery performed by a single surgeon, older adults did not appear to have more complications than younger patients.
Thyroid surgery safe for older patients, study finds
Thyroid surgery is safe for older patients, say physicians who found only slight differences in rates of complications and hospital readmissions in a multi-year study.
Researchers pinpoint a new enemy for tumor-suppressor p53
Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells.
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer.
First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
New guidelines designed to standardize and optimize the diagnosis, treatment, and monitoring of patients with Medullary Thyroid Carcinoma (MTC), an uncommon and challenging form of thyroid cancer, have been developed by the American Thyroid Association.
Drug that targets vasculature growth attacks aggressive thyroid cancer
A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.
Metastatic bone disease patients can walk in Lazarus' footsteps
Osteoplasty-a highly effective minimally invasive procedure to treat the painful effects of metastatic bone disease by injecting bone cement to support weakened bones-provides immediate and substantial pain relief, often presenting individuals who are suffering terribly with the miraculous so-called "Lazarus effect," according to researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting.
Mayo Clinic Researchers Find Experimental Therapy Turns on Tumor Suppressor Gene in Cancer Cells
Researchers at Mayo Clinic have found that the experimental drug they are testing to treat a deadly form of thyroid cancer turns on a powerful tumor suppressor capable of halting cell growth. Few other cancer drugs have this property, they say.
Molecular imaging enables earlier, individualized treatment of thyroid cancer
In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.
More Thyroid Cancer Current Events and Thyroid Cancer News Articles
 |
The Thyroid Cancer Book by M. Sara Rosenthal; Ph.D. (Author) M. Sara Rosenthal, Ph.D., bestselling author of The Thyroid Sourcebook (recommended by The New York Times), The Thyroid Sourcebook for Women and The Hypothyroid Sourcebook has just published The Thyroid Cancer Book, the only consumer book to date devoted to thyroid cancer. A thyroid cancer survivor herself, Rosenthal wrote the book she wishes she'd had when diagnosed in 1983. The Thyroid Cancer Book explains all forms of thyroid cancer and its treatment in plain language. It was written in consultation with the leading medical experts on thyroid cancer in North America, and is the only book of its kind in the world. It includes extensive information on: * Significant risk factors for developing the disease, and how to find and investigate lumps in the neck |
 |
Thyroid Cancer: A Guide for Patients by D. Van Nostrand (Author), G. Bloom (Author), L. Wartofsky (Author) This book is a valuable and extensive source of information about thyroid cancer and is specifically written for the patient with thyroid cancer. However, family and friends of patients who have thyroid cancer will also find this book useful. The book discusses a wide spectrum of aspects about thyroid nodules and cancer. It is discusses the basics of the thyroid gland, the evaluation of thyroid nodules, the various types of thyroid cancer, their prognosis, and the initial diagnostic evaluation and treatment of the four major types of thyroid cancer. This includes the role of surgery and other treatments. The book also discusses diets, hormone treatment, and thyroid cancer in children and adolescents. One chapter presents the personal stories of several patients, who have or... |
 |
Quick FACTS Thyroid Cancer: What you need to knowNow (ACS Quick Facts Series) by American Cancer Society (Author) What people need to know-right from the start-about their Thyroid cancer More than 1.3 million Americans will be diagnosed with various forms of cancer this year. They, their families, and their caregivers will all be seeking information about their specific cancer type. This guide from the experts at the American Cancer Society gives them what they need to know, right from the start. |
 |
Essentials of Thyroid Cancer Management (Cancer Treatment and Research) by Robert J. Amdur (Editor), Ernest L. Mazzaferri (Editor) This volume outlines patient care from diagnosis through various treatments for thyroid cancer patients. It serves as a state-of-the-art reference for clinicians providing comprehensive information on the scope of this disease, including surgery, nuclear medicine treatments, recurrence and metastases. Reference information is included for both physicians and thyroid cancer patients. |
 |
Thyroid Cancer for Beginners by Glenda Shepherd (Author) Thyroid Cancer For Beginners I hope will be informative for anyone newly diagnosed. It charts my four-year journey from first finding a lump in my neck, through surgery to remove the thyroid gland and subsequently being given a diagnosis of papillary thyroid cancer. Also, the reader will find out what happens during radioactive Iodine treatment, and how I felt at the time after having to undergo further surgery to remove cancerous lymph nodes some two years later. It includes snippets of family life, and the effect my illness had on my immediate family. |
 |
The Purple Butterfly: Diary of a thyroid cancer patient by Susan Hibberd (Author) ’The Purple Butterfly’ cameos a year in the life of a thyroid cancer patient. Restrained and sparsely written, it gives the reader a deep insight into the mind of someone who is balancing on the edge of hysteria, yet still feels an obligation to ‘put on a brave face’. A 'must-read' for anyone supporting a friend or relative through a serious illness - this book tells you what he or she never will. The volume also contains ‘Flying with the Purple Butterfly, which is a manual for those about to undergo radioactive iodine treatment. Based on personal experience, this the first time this information has been published in the UK. Background: ‘The Purple Butterfly’ is not a work of fiction. It is the real diary kept by Susan from March 2003 to February 2004, and... |
 |
The Thyroid Sourcebook (5th Edition) (Sourcebooks) by M. Sara Rosenthal (Author) The classic reference guide for living with thyroid disorder--now completely revised and updated The New York Times called this book "an excellent source of information." The Thyroid Sourcebook features patient narratives; information on the complications of hypo- and hyperthyroidism, such as depression, weight gain, thyroid, eye disease, and sleep disorders; the latest on complimentary medicine; and much more. |
 |
Practical Management of Thyroid Cancer: A Multidisciplinary Approach by Ernest L. Mazzaferri (Editor), Clive Harmer (Editor), Ujjal K. Mallick (Editor), Pat Kendall-Taylor (Editor) Written by a multidisciplinary team of experts involved in the development of standards and guidelines for its management in the USA, UK, Europe and Asia, the book contains succinct and knowledgeable summaries of the management of thyroid cancer. Every chapter describes a different aspect of care, and provides clear and detailed information about caring for patients with this group of tumors. The book follows the American and European model of treating thyroid cancer according to the high standards recommended by the available guidelines. This is an invaluable reference to health care professionals, from primary to tertiary care, involved in the management of thyroid cancer such as clinical nurse specialists, clinical psychologists, family medicine practitioners,... |
 |
Cure Thyroid Cancer Sweatshirt Large White by Shop Zeus |
 |
Thyroid Cancer: A Comprehensive Guide to Clinical Management by Leonard Wartofsky (Editor), Douglas Van Nostrand (Editor) This massive revision of the highly acclaimed first edition presents a wealth of new information and insights on every aspect of the etiology, pathogenesis, diagnosis, initial treatment, and long-term management of all varieties of thyroid cancer. Paramount is a thorough treatment of the nuclear medical aspects of diagnosing and managing the thyroid cancer patient. This includes extensive discussion of isotopes, isotope uptake and scanning procedures, radioisodine ablation and dosimetry (with or without recombinant human TSH), stunning, octreotide and FDG-PET scanning, and various alternative imaging modalities. Additional highlights include management of the scan negative and thyroglobulin-positive patient, ultrasound of the lymph nodes, local adjuncts to therapy of metastases, low... |
| © 2009 BrightSurf.com |